TY  -  
T1  - Acute hypoxemic respiratory failure in immunocompromised patients : the Efraim multinational prospective cohort study 
SN  -  /  
UR  - http://hdl.handle.net/10138/283172 
T3  -  
A1  - Azoulay, Elie; Pickkers, Peter; Soares, Marcio; Perner, Anders; Rello, Jordi; Bauer, Philippe R.; van de Louw, Andry; Hemelaar, Pleun; Lemiale, Virginie; Taccone, Fabio Silvio; Loeches, Ignacio Martin; Meyhoff, Tine Sylvest; Salluh, Jorge; Schellongowski, Peter; Rusinova, Katerina; Terzi, Nicolas; Mehta, Sangeeta; Antonelli, Massimo; Kouatchet, Achille; Barratt-Due, Andreas; Valkonen, Miia; Landburg, Precious Pearl; Bruneel, Fabrice; Bukan, Ramin Brandt; Pene, Frederic; Metaxa, Victoria; Moreau, Anne Sophie; Souppart, Virginie; Burghi, Gaston; Girault, Christophe; Silva, Ulysses V. A.; Montini, Luca; Barbier, Francois; Nielsen, Lene B.; Gaborit, Benjamin; Mokart, Djamel; Chevret, Sylvie; Efraim Investigators; Nine-I Study Grp 
A2  -  
PB  -  
Y1  - 2017 
LA  - eng 
AB  - In immunocompromised patients with acute hypoxemic respiratory failure (ARF), initial management aims primarily to avoid invasive mechanical ventilation (IMV). To assess the impact of initial management on IMV and mortality rates, we performed a multinational observational prospective cohort study in 16 countries (68 centers). A total of 1611 patients were enrolled (hematological malignancies 51.9%, solid tumors 35.2%, systemic diseases 17.3%, and solid organ transplantation 8.8%). The main ARF ... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - Noninvasive ventilation; High flow oxygen; Hematological malignancies; Transplantation; Systemic diseases; Pneumocystis; CRITICALLY-ILL PATIENTS; NONINVASIVE VENTILATION; INFLAMMATORY DISEASES; HEMATOLOGY PATIENTS; BIOLOGIC THERAPIES; OUTCOMES; CANCER; TRIAL; IMMUNOSUPPRESSION; MALIGNANCIES; 3121 General medicine, internal medicine and other clinical medicine 
N1  -   
PP  -  
ER  -